ClinicalTrials.gg
RecruitingNCT03500107Updated Mar 5, 2024

Use of Blue Light Emitting Diode in the Treatment of Women With Bacterial Vaginosis: a Clinical Trial

An interventional study of Blue Light Emitting Diode (LED) 401 +/- 5nm in Vaginosis, Bacterial, sponsored by Centro de Atenção ao Assoalho Pélvico. Recruiting at 1 site in Brazil. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by Centro de Atenção ao Assoalho Pélvico · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2018; still recruiting 8 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

Bacterial Vaginosis (BV) is a infectious process of the female genitourinary tract, an important health issue due to the high incidence and high rate of recurrence of the infection. Therefore, new therapeutic modalities are sought with the capacity to minimize drug side effects and reduce cases of recurrence of the disease. The objective of this study is to evaluate the clinical and microbiological response of the 401+/- 5nm blue light emitting diode (LED) in the treatment of women with bacterial vaginosis. The group of women with diagnosis of bacterial vaginosis will be submitted to the light therapy. These women will also be submitted to an evaluation and examination by a ginecologist before and after the therapy. There will also be an evaluation of the clinical condition and about the effects of the light through the questionnaire answered before and after participant's treatment. It's expected that the 41 +/- 5nm LED will destroy the VB demonstrated by laboratory examination and also improves the signs and results analyzed by the gynecologist and participants.

Read the detailed description

A current treatment proposal is the use of blue LED of 401 +/- 5 nm wich is a light that has antimicrobial effect when exposed to endogenous porphyrin of the pathogens. This exposition produces reactive oxygen and it causes cells death with no possibilities of resistance by the bacterium.

02

Conditions studied

  • Vaginosis, Bacterial

Browse trials for

Keywords

  • Blue Light Emitting Diode
  • Women
03

In context

Vaginosis, Bacterial

240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.

This study's planned enrollment of 40 is below the median of 100 across 203 interventional studies indexed under Vaginosis, Bacterial.

Browse Vaginosis, Bacterial studies →

Lead sponsor

Centro de Atenção ao Assoalho Pélvico is the lead sponsor of 17 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with 18 to 65 years old and with diagnosis of bacterial vaginosis

Exclusion criteria

Exclusion Criteria:

  • women with injury seen by Pap smear, or in use of pacemaker, with diagnosis or suspicion of neoplasias, with heart diseases, pregnant or with diagnosis of epilepsy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Blue LED 401 +/- 5 nm

    The Blue LED 401 +/- 5 nm will be applied in the participant, in a closed room by a physiotherapist for 1 hour. The apparatus will be supported on a tripod, statically, externally, 5 cm away from the vulva abd vaginal region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol consists of only one session. This part of the study will see if there is bactericidal effect of the blue LED.

    Device: Blue Light Emitting Diode (LED) 401 +/- 5nm

Interventions

  • DeviceBlue Light Emitting Diode (LED) 401 +/- 5nm

    The participant will be naked, in a gynecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.

    Also known as: Questionnaire of anamnesis

06

What researchers measure

Primary outcomes

  1. Description of types of cells done by oncology and microflora cytology in women treated by blue LED of 401 +/- 5nm

    This exam will be done by the collect of vaginal secretion to analyze types of cells and organisms

    Time frame: 15 days

  2. Amount of clue cells quantified by fresh cytology in vaginal secretion of women treated by blu LED of 401 +/- 5nm

    This exam will be done by the collect of vaginal secretion using KOH 10%

    Time frame: 10 minutes

  3. Value of vaginal pH measurement in women treated by blue LED

    This exam will be done by the collect of vaginal secretion using a pH measuring tape to analyse the hydrogen potential in -log 10 \[pH+\] in women treated by blue LED. It will be used the numeric scale of pH value

    Time frame: 2 minutes

  4. Identification of bacterial vaginosis by the culture in vaginal secretion of women treated by blue LED

    This exam will be done by the collect of vaginal secretion using a Gram exam / culture for bacteria in women treated by blue LED

    Time frame: 15 days

07

Study locations

1 of 1 sites recruiting
  • Cebtro de Atebçao ao Assolaho Pévico- Escola Bahiana de Medicina e Saúde Pública
    Salvador, Bahia 40290000, Brazil
    Recruiting
    • Patrícia Lordelo, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2018 (actual). Primary completion is estimated for Dec 2024, 74 months after the start.

Of 52 interventional studies with no phase under Vaginosis, Bacterial, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 56. This study's planned 74 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2018
First posted
Apr 17, 2018
StartActual
Oct 2, 2018
Primary completionEst.
Dec 20, 2024
CompletionEst.
Dec 20, 2025
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03500107
Lead sponsor
Centro de Atenção ao Assoalho Pélvico
Collaborators
University of Messina, Salvatore Giovanni Vitale M.D.
Responsible party
Sponsor
First posted
Apr 17, 2018
Start date
Oct 2, 2018
Primary completion
Dec 20, 2024 (estimated)
Completion
Dec 20, 2025 (estimated)
Last update
Mar 5, 2024

Study contacts

Patricia Lordelo
Contact
pvslordelo@hotmail.com
+55 71 3330 1640
Patricia Lordelo
Contact
pvslordelo@hotmail.com
+55 71 3276 8260
Patricia Lordelo
study director · Centro de Atenção ao Assoalho Pélvico

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion